2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - La Nouvelle A-B
Technology and Procedures, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Adverse Events, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult
PAPER

820 Putting the spliceosome on the RADAR: Long-read RNA sequencing in the UKMRA RADAR trial reveals hidden isoforms of myeloma drivers and therapeutic targets.

Bethan Hudson-Lund, PhD, Anandagopal Srinivasan, MA MB BChir2, Eleanor Calcutt3, Emma Lyon4, Jessica Kimber5, Alice Lefever6, Annabel Laidler7, Elise Rees, PhD8, Amatta Mirandari, PhD9, Daniel Hughes, MBBS, MRCP10, Louise Ainley, MD11, Janice Sim12, Jongwon Yoon, PhD13, Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath(Haem), PhD14, Maximilian Goodman15, Megan Hawksley16, Angela Brown17, Mohammad Kazeroun, PhD18, Naser Ansari-Pour19, Matthew Jenner, MBBS20, Laura Chiecchio21, Martin F Kaiser, MD,FRCP,FRCPath22, Michael Chapman, PhD23, Angela Hamblin24, Lorna Barnard25, Kara-Louise Royle, PhD26, Robert Cicero27, David Cairns, PhD28, Catherine Olivier29, Sharon Jackson30, Charlotte Kennaway31, Gordon Cook32, Guy Pratt33, Alan Chant34, Jonathan Sive, MD35, Christopher Parrish, PhD, FRCPath, MA, MBBChir, MRCP36, Udo Oppermann37, Karthik Ramasamy, MD PhD38, Kwee Yong, Prof39, Eileen Boyle, MD PhD40, Sarah Gooding, MD PhD41, Adam Cribbs, Prof42
1 University College London, London, United Kingdom
2 University of Oxford, Oxford, United Kingdom
3 University of Oxford, Oxford, United Kingdom
4 University College London, London, United Kingdom
5 University College London, London, United Kingdom
6 University College London, London, United Kingdom
7 University College London, London, United Kingdom
8 University College London, London, United Kingdom
9 University College London, London, United Kingdom
10 University College London, London, United Kingdom
11 University College London, London, United Kingdom
12 University College London, London, United Kingdom
13 University College London, London, United Kingdom
14 University College London, London, United Kingdom
15 Oxford University Hospitals NHS Foundation trust, Oxford, United Kingdom
16 Oxford University Hospitals NHS Foundation trust, Oxford, United Kingdom
17 Oxford University Hospitals NHS Foundation trust, Oxford, United Kingdom
18 University of Oxford, Oxford, United Kingdom
19 Oxford University Hospitals NHS Foundation trust, Oxford, United Kingdom
20 University Hospital Southampton, Southampton, United Kingdom
21 University of Southampton, Southampton, United Kingdom
22 The Institute of Cancer Research, London, United Kingdom
23 University of Cambridge, Cambridge, United Kingdom
24 University of Oxford, Oxford, United Kingdom
25 University of Leeds, Leeds, United Kingdom
26 University of Leeds, Leeds, United Kingdom
27 University of Leeds, Leeds, United Kingdom
28 University of Leeds, Leeds, United Kingdom
29 University of Leeds, Leeds, United Kingdom
30 University of Leeds, Leeds, United Kingdom
31 University of Leeds, Leeds, United Kingdom
32 Leeds Teaching Hospitals Trust, Leeds, United Kingdom, University of Leeds, Leeds, United Kingdom
33 University of Birmingham, Birmingham, United Kingdom
34 Patient and Public Representative, London, United Kingdom
35 University College Hospital, London, United Kingdom
36 Leeds Teaching Hospitals Trust, Leeds, United Kingdom, University of Leeds, Leeds, United Kingdom
37 University of Oxford, Oxford, United Kingdom
38 Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, University of Oxford, Oxford, United Kingdom
39 University College London, London, United Kingdom
40 University College London, London, United Kingdom
41 University of Oxford, Oxford, United Kingdom
42 University of Oxford, Oxford, United Kingdom

Alternatively spliced RNA transcript isoforms have been shown to alter function, drive disease progression, and confer immune resistance in myeloma. However, insight into underlying biology and therapeutic opportunities is limited by current short-read RNA technologies that poorly map disease-specific isoforms and result in ambiguous splice junctions. We have shown that long-read RNA sequencing identifies genetic and transcriptomic myeloma risk markers in a one-platform test (IMS 2026), enabling risk prediction integration with novel isoform calling. In this study, we highlight novel spliced isoforms of myeloma driver genes and therapeutic targets at diagnosis that affect function and clinical outcome.

Using Oxford Nanopore Technologies long-read RNA sequencing, we sequenced CD138+ cells from 131 diagnostic biopsies in the UKMRA RADAR trial: a multicentre, risk-adapted, response-guided phase III trial in transplant-eligible newly diagnosed myeloma. Genomic aberrations were annotated using FISH and targeted region DNA sequencing via the Myeloma Genome Panel. For long-read RNA analysis, we developed specialised pipelines TallyTriN and Splifastqcats (github.com/acribbs) to ensure high-quality pre-processing and UMI correction of published homotrimer primers for accurate variant calling. Bambu and Sqanti3, the gold-standard for long-read isoform analysis, were used for isoform quantification and classification, and Ensembl and APPRIS databases for biological annotation. Isoforms were also filtered by count and relative expression. Validation of novel isoforms was achieved by qPCR verification using reverse-transcribed patient RNA.

We report an average of 2.3 different isoforms per gene (range 1-33) across diagnostic samples, with novel isoforms revealed in 20% of genes due to the improved resolution of long-read sequencing. 3% of genes showed higher alternative transcript expression than the canonical, of which 70% were protein-coding. These included transcription factors (RUNX3, IKZF3), epigenetic regulators (KMT2A, EZH2), splicing factors (SRSF11, U2AF2), oncogenes (MYC, KRAS) and tumour suppressors (TP53). Alternative isoform usage increased with ISS stage (p=0.049) and in high-risk patients with double-hit aberrations (p=0.029). While translocation group did not influence isoform abundance, patients with DUOX2 mutations (n=12) linked to ROS generation were found to have more isoforms per gene and more novel isoforms (FDR=0.078 and 0.053).

Alternative isoforms were detected in 86% of myeloma driver genes, and novel isoforms were detected in 17%, with all patients expressing at least one novel driver transcript. 12% of drivers expressed isoforms with novel splice junctions, of which KRAS and BLIMP1 were confirmed by qPCR with comparable abundance to housekeeping genes. Although globally most novel isoforms were predicted to be non-coding, in driver genes 65% of them resulted in a predicted novel open reading frame. We identified previously annotated alternative transcripts such as KRAS4A vs KRAS4B, with distinct C-terminal domains that alter localisation, as well as novel transcripts including a KRAS truncated isoform with the catalytic domain conserved. These findings highlight candidate isoforms for future functional studies.

Finally, we identified novel isoforms of immunotherapeutic targets with potential functional consequences for treatment response. While no novel isoforms were detected for CD38 or BCMA, novel splicing events in GPRC5D and FcRL5 occurred in 98% and 27% of patients, with increased expression relative to canonical transcripts (GPRC5D) or predicted loss of the transmembrane domain (FcRL5), potentially affecting targetability. We identified both previously described and novel CRBN isoforms with exon 10 skipping, shown to predict an inferior response to lenalidomide-based treatment. Alternative isoform expression may also influence utility of diagnostics: we identified a HK2 novel isoform lacking exon 5, which may influence PET sensitivity due to reduced hexokinase activity.

This work uncovers a previously under-recognised layer of transcriptomic complexity in myeloma, with the discovery of novel transcript isoforms in drivers and targets with clinically actionable pathways. These findings provide new insights into the molecular mechanisms underlying disease heterogeneity, clinical presentation, and treatment response, providing opportunities for improving personalised approaches to therapeutic management.

Bethan Hudson-Lund, PhD: No relevant conflicts of interest to declare.